NCT05550558View on ClinicalTrials.gov

Camrelizumab Plus Anlotinib in Patients With Recurrent Sporadic MMRd Endometrial Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

November 1, 2022

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2027

Conditions
Endometrial Cancer
Interventions
DRUG

Anlotinib + Camrelizumab

Anlotinib PO plus Camrelizumab IV

All Listed Sponsors
lead

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER

NCT05550558 - Camrelizumab Plus Anlotinib in Patients With Recurrent Sporadic MMRd Endometrial Cancer | Biotech Hunter | Biotech Hunter